LXEO SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 12, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 11, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 30, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 14, 2025

10-Q/A

Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]

May 14, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Lexeo Therapeutics Completes Acquisition of Mantle Therapeutics Inc.

Sep 29, 2026

8-K

Lexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich A

Sep 22, 2026

8-K

Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights

Aug 12, 2026

8-K

Lexeo Therapeutics, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 29, 2026

8-K

Lexeo Therapeutics Finalizes Pivotal Trial Design for LX2006 Gene Therapy in Friedreich Ataxia

Jun 15, 2026

8-K

Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights

May 11, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 1,250,015

Nov 26, 2025

424B5

REGISTERED OFFERING

Oct 17, 2025

424B5

PENDING FIXED PRICE OFFERING | Warrants exercise price: $8.82 | Bank: Leerink Partners, Cantor, Stifel, Oppenheimer & Co.

Oct 16, 2025

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 41,630,514 | Warrants amount: 20,000,000 |

Jul 1, 2025

424B5

March 2025 ATM

Mar 24, 2025

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 6,974,248

Nov 13, 2024

Registrations

TYPE

HEADLINE

FILED AT

S-3

October 2026 SHELF EFFECTIVE, DATED 2026-11-04

Oct 29, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 30, 2026

S-3

SHARE RESALE REGISTRATION

Nov 5, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Nov 5, 2025

FWP

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses

Oct 17, 2025

FWP

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses

Oct 16, 2025

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 30, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 30, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Jun 5, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 28, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 28, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 26, 2024

Ownerships

TYPE

HEADLINE

FILED AT

S-3

Form S-3 - Registration statement under Securities Act of 1933

Oct 29, 2026

SCHEDULE 13G

JPMORGAN CHASE & CO (Filed by)

Oct 13, 2026

Tamayo Louis Edward (Reporting)

Sep 28, 2026

Bhalla Narinder Pal (Reporting)

Sep 28, 2026

Otero Jose Manuel (Reporting)

Sep 28, 2026

Townsend Richard Nolan (Reporting)

Sep 28, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Nov 5, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Nov 28, 2025

CORRESP

Form CORRESP - Correspondence

Nov 25, 2025

EFFECT

Form EFFECT - Notice of Effectiveness

Jul 1, 2025

CORRESP

Form CORRESP - Correspondence

Jun 27, 2025

CORRESP

Form CORRESP - Correspondence

Jun 26, 2025

Lexeo Therapeutics, Inc. Common Stock LXEO · SEC Filings